CathWorks is developing an image-based functional flow reserve (FFR) measurement during coronary catheterization, replacing the pressure-wire based, drug-induced measurement currently performed. CathWorks angiogram-based FFR (FFRangio) has met the need for a less invasive FFR assessment tool, to improve real-time functional assessment leading to treatment decisions, and to make coronary catheterization procedures safer, shorter, more accurate and comprehensive.

Medical Device
Private
Visit Website
Additional Portfolio Companies
Adicet Bio
ArQule
BioBlast Pharma
Cathworks
cCAM Biotherapeutics
CheckCap
Eloxx Pharmaceuticals
Enlivex Therapeutics
Entera Bio
Eyevensys
EyeYon
ForSight Vision6 (“V6”)
Hairstetics
Headsense
Horama
Keros Therapeutics
Kite Pharma
LogicBio Therapeutics
Metabomed
NovellusDX
Novus Therapeutics
Ocon Medical
PACT Pharma
Pi Therapeutics
Protalix
Raziel Therapeutics
ReWalk
VBI Vaccines
Step Pharma
StimatixGI
Sweetch
TargEDys
UroGen
V-Wave
August 27, 2015